Idiopathic pulmonary fibrosis and a role for autoimmunity

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is typically associated with extensive and progressive fibrosis, and is fatal and has limited treatment options. Characteristically IPF patients display large lymphocyte aggregates composed of CD3+ T...

Full description

Saved in:
Bibliographic Details
Published in:Immunology and cell biology 2017-08, Vol.95 (7), p.577-583
Main Authors: Hoyne, Gerard F, Elliott, Hannah, Mutsaers, Steven E, Prêle, Cecilia M
Format: Article
Language:English
Subjects:
Animals
Antigens
Autoantibodies
Autoimmunity
B-Lymphocytes - immunology
CD20 antigen
CD3 antigen
Fibrosis
Humans
Idiopathic Pulmonary Fibrosis - immunology
Idiopathic Pulmonary Fibrosis - pathology
Immune Tolerance
Immunological tolerance
Immunotherapy
Lung diseases
Lymphocytes B
Lymphocytes T
Models, Immunological
Patients
Pulmonary fibrosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is typically associated with extensive and progressive fibrosis, and is fatal and has limited treatment options. Characteristically IPF patients display large lymphocyte aggregates composed of CD3+ T cells and CD20+ B cells within the lung tissue that are located near sites of active fibrosis. In addition, IPF patients can have autoantibodies to a range of host antigens, suggesting a breakdown in immunological tolerance. In this review, we examine the role of T and B cells in IPF pathogenesis and discuss how loss of self‐tolerance to lung‐specific proteins could exacerbate disease progression in IPF. We discuss what these results mean in terms of future prospects for immunotherapy of IPF.
ISSN:0818-9641
1440-1711
DOI:10.1038/icb.2017.22